MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence

Abstract

BACKGROUND:

Urinary bladder carcinoma is one of the leading causes of death among men, and its high recurrence rates make it one of the most solid tumors to treat. The silencing of the tumor suppressor gene by hypermethylation of the CpG islands and overexpression of proto-oncogene proteins are the main mechanisms in cancers. Here, we investigate methylation status of O6-methylguanine-DNA-methyltransferase (MGMT), a tumor suppressor gene and expression level of BCL-2 a proto-oncogene protein that is frequently observed in bladder carcinoma and its recurrences.

MATERIALS AND METHODS:

We analyzed the methylation of MGMT in 80 tissue samples of patients suffering from bladder cancer and 80 urine samples of cancer-free individuals by MS-PCR. Additionally, BCL-2 protein expression level was analyzed on these 80 tissue samples by immunohistochemistry.

RESULTS:

45% of patients had MGMT methylation, of which this hypermethylation does not have significant association with an increase in grade, but there was significant association in cases with recurrence tumors and metastasis tumors. Among patients with recurrence tumor, 92.5% patients showed MGMT hypermethylation; 66% of these showed BCL-2 overexpression.

CONCLUSION:

Our data indicate that MGMT hypermethylation and BCL-2 overexpression may have an intense role in superficial bladder cancer recurrences.

Keywords

Bladder cancer methylation tumor suppressor gene MGMT BCL-2

References

Siegel,

, Naishadham

, and Jemal

, Cancer statistics, 2013. CA Cancer J Clin, 2013. 63(1): p. 11-30.

Iranian Ministry of Health and Medical Education, H.D., Department of Prevention of Non Contagious Diseases, Iranian Annual of National Cancer Registration Report 2009/2010, (In Persian). 2012.

StatBite: A look at bladder cancer in the United States. J Natl Cancer Inst, 2009. 101(22): p. 1533.

Kaina,

, et al., MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst), 2007. 6(8): p. 1079-99.

Gerson,

S.L.

, MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer, 2004. 4(4): p. 296-307.

Pegg,

A.E.

, Dolan

M.E.

, and Moschel

R.C.

, Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol, 1995. 51: p. 167-223.

Jones,

P.A.

and Laird

P.W.

, Cancer epigenetics comes of age. Nat Genet, 1999. 21(2): p. 163-7.

Pongtheerat,

, et al., Promoter methylation and genetic polymorphism of glutathione S-transferase P1 gene (GSTP1) in Thai breast-cancer patients. Asian Pac J Cancer Prev, 2011. 12(10): p. 2731-4.

Kaina,

and Christmann

, DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther, 2002. 40(8): p. 354-67.

10.

Larijani,

, et al., Methylation of O6-methyl guanine methyltransferase gene promoter in meningiomas-comparison between tumor grades I, II, and III. Asian Pac J Cancer Prev, 2014. 15(1): p. 33-8.

11.

Xiong,

H.L.

, et al., Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. Asian Pac J Cancer Prev, 2013. 14(5): p. 3139-42.

12.

Agundez,

, et al., Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours. Eur Urol, 2011. 60(1): p. 131-40.

13.

Bilgrami,

S.M.

, et al., Promoter hypermethylation of tumor suppressor genes correlates with tumor grade and invasiveness in patients with urothelial bladder cancer. Springerplus, 2014. 3: p. 178.

14.

Hanahan,

and Weinberg

R.A.

, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-70.

15.

Del Poeta,

, et al., Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood, 2003. 101(6): p. 2125-31.

16.

Amundson,

S.A.

, et al., An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res, 2000. 60(21): p. 6101-10.

17.

Strasser,

, et al., Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature, 1990. 348(6299): p. 331-3.

18.

Kuo,

M.L.

, et al., Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis. Mol Pharmacol, 1999. 55(5): p. 894-901.

19.

Youn,

C.K.

, et al., Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat Cell Biol, 2005. 7(2): p. 137-47.

20.

Sartorius,

U.A.

and Krammer

P.H.

, Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer, 2002. 97(5): p. 584-92.

21.

Mena,

, et al., Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease. Clin Cancer Res, 2007. 13(9): p. 2658-66.

22.

Kouraklis,

, et al., Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer. Dig Dis Sci, 2003. 48(12): p. 2284-9.

23.

Herman,

J.G.

, et al., Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 1996. 93(18): p. 9821-6.

24.

Righini,

C.A.

, et al., Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res, 2007. 13(4): p. 1179-85.

25.

Yates,

D.R.

, et al., Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res, 2007. 13(7): p. 2046-53.

26.

Kang,

G.H.

, et al., Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol, 2004. 202(2): p. 233-40.

27.

Nakamura,

, et al., Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C \to A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis, 2001. 22(10): p. 1715-9.

28.

Edwards,

B.K.

, et al., Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer, 2010. 116(3): p. 544-73.

29.

Rao,

J.Y.

, et al., Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci U S A, 1993. 90(17): p. 8287-91.

30.

Tada,

, et al., The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res, 2002. 62(14): p. 4048-53.

31.

Kang,

M.H.

and Reynolds

C.P.

, Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res, 2009. 15(4): p. 1126-32.

32.

Scorrano,

and Korsmeyer

S.J.

, Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun, 2003. 304(3): p. 437-44.

33.

Reed,

J.C.

, Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood, 2008. 111(7): p. 3322-30.

34.

Schwandner,

, et al., p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer, 2000. 36(3): p. 348-56.

35.

Karam,

J.A.

, et al., Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol, 2007. 8(2): p. 128-36.

36.

Joung,

J.Y.

, et al., Identification of Immunohistochemical Factors That Predict the Synchronous or Metachronous Development of Bladder Tumors in Patients with Upper Urinary Tract Tumors. Urologia Internationalis, 2008. 81(3): p. 306-311.

37.

Yoshino,

, et al., Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res, 2006. 12(20 Pt 1): p. 6116-24.